skip to the content

Efficacy in combination with a broad range of standard therapies

  • Combining anticancer agents with different MoA may lead to increased efficacy through additive, and even synergistic, effects

    • the precise nature of VEGF inhibition by Avastin makes this agent an ideal partner for combination with approaches aimed at other mechanisms of tumour proliferation.24,25

  • Additional benefit may be gained through normalisation of tumour vasculature by Avastin, which reduces interstitial pressure and increases the delivery of other agents to the tumour. 26,27

  • This section provides an overview of the clinical efficacy of Avastin in combination with different types of anticancer agent.